Table 1.
Patients with Pulmonary Arterial Hypertension in the Data Base of Pulmonary Hypertension in the Polish Population (BNP-PL) Registry.
| All | I/HPAH | CTD | CHD | Portal | Drugs/ Toxins |
HIV | |
|---|---|---|---|---|---|---|---|
| No of patients | 970 | 444 | 132 | 356 | 25 | 7 | 6 |
| Age (years) | 46.8 ± 22.3 | 54.6 ± 18.2 | 60.4 ± 13.9 | 31.5 ± 21.6 | 53.7 ± 21.6 | 57.1 ± 14.4 | 37.7 ± 5.0 |
| Data acquired at diagnosis | |||||||
| WHO FC, n (%) | |||||||
| I | 6 (0.6) | 3 (0.8) | 1 (0.8) | 2 (0.6) | 0 | 0 | 0 |
| II | 159 (16.4) | 76 (17) | 17 (12.9) | 56 (15.7) | 6 (24.0) | 2 (28.6) | 2 (33.3) |
| III | 699 (72.1) | 293 (66) | 96 (72.7) | 289 (81.2) | 16 (64.0) | 2 (28.6) | 3 (50.0) |
| IV | 106 (10.9) | 72 (16.2) | 18 (13.6) | 9 (2.5) | 3 (12.0) | 3 (42.8) | 1 (16.7) |
| Age (years) | 53.8 ± 17.9 | 58.7 ± 16.9 | 63.8 ± 13.1 | 43.8 ± 16.3 | 56.4 ± 14.6 | 58.2 ± 12.9 | 41.1 ± 5.4 |
| Data acquired at enrollment | |||||||
| Female, n (%) | 677 (69.8) | 318 (71.6) | 115 (87.1) | 223 (62.4) | 15 (60) | 3 (42.9) | 3 (50) |
| Incident cases, n (%) | 96 (9.9) | 48 (10.8) | 20 (15.1) | 19 (5.3) | 5 (20) | 1 (14.3) | 3 (50) |
| WHO FC, n (%) | |||||||
| I | 49 (5.1) | 28 (6.5) | 6 (1.5) | 13 (4.8) | 0 | 2 (28.6) | 0 |
| II | 455 (46.9) | 200 (45.3) | 52 (44.8) | 187 (49.4) | 12 (48) | 2 (28.6) | 2 (33.3) |
| III | 429 (43.8) | 195 (43.4) | 64 (48.5) | 151 (41.8) | 13 (52) | 2 (28.6) | 4 (66.7) |
| IV | 37 (4) | 21 (3.8) | 10 (5.2) | 5 (4) | 0 | 1 (14.3) | 0 |
| 6 MWD [m] | 375 ± 142 | 383 ± 151 | 344 ± 138 | 375 ± 132 | 376 ± 143 | 415.2 ± 74 | 408 ± 159 |
| BMI [kg/m2] | 25.8. ± 5.5 | 27.3 ± 5.4 | 25.3 ± 5.1 | 23.9 ± 5.4 | 26.1 ± 4.5 | 26.4 ± 7.9 | 22.6 ± 4.9 |
| NTproBNP [ng/l] * | 1446 ± 2733 | 1480 ± 2815 | 1881 ± 2526 | 1262 ± 2566 | 910 ± 1923 | 4328 ± 6926 | 2529 ± 2834 |
| BNP [ng/l] * | 310 ± 648 | 382 ± 761 | 316 ± 538 | 237.8 ± 558 | - | - | - |
| mPAP [mmHg] | 50.6 ± 18.9 | 45.1 ± 13.9 | 38.4 ± 12.6 | 63.4 ± 21.8 | 45.7 ± 8.8 | 41.0 ± 19.7 | 46.5 ± 13.8 |
| PVR [WU] | 7.8 ± 4.2 | 8.1 ± 4.2 | 7.0 ± 4.2 | 14.9 ± 9.9 | 6.8 ± 2.8 | 6.7 ± 5.6 | 8.8 ± 5.2 |
| CI [l/min/m2] | 2.7 ± 0.8 | 2.7 ± 1.8 | 2.7 ± 0.7 | 2.5 ± 1.1 | 3.2 ± 1.2 | 2.8 ± 1.0 | 2.7 ± 0.9 |
| RAP [mmHg] | 6.7 ± 4.3 | 6.7 ± 4.3 | 6.2 ± 4.3 | 7.0 ± 4.1 | 7.5 ± 4.3 | 8.2 ± 3.5 | 7.5 ± 5.3 |
| PAWP [mmHg] | 8.9 ± 3.3 | 9.4 ± 3.3 | 9.3 ± 3.2 | 8.2 ± 3.4 | 9.3 ± 3.5 | 7.0 ± 2.5 | 8.2 ± 3.5 |
| RAA [cm2] | 23.9 ± 9.2 | 24.6 ± 9.2 | 23.9 ± 9.8 | 22.4 ± 7.45 | 22.4 ± 8.7 | 23.9 ± 5.9 | 21.4 ± 8.6 |
* patients with chronic dialysis were excluded from the assessment of brain natriuretic peptide; in two centres BNP was used instead of NT-proBNP. BMI—body mass index, CI—cardiac index, mPAP—mean pulmonary artery pressure, 6 MWD—six min walking distance, NT-proBNP—N-terminal pro-B-type Natriuretic Peptide, PAWP—pulmonary artery wedge pressure, PVR—pulmonary vascular resistance, RAA—right atrial area, RAP – right atrial pressure, WHO FC—World Health Organization Functional Class WU—Wood unit.